Susquehanna International Group LLP Acquires New Holdings in Tenax Therapeutics Inc (NASDAQ:TENX)

Susquehanna International Group LLP acquired a new stake in shares of Tenax Therapeutics Inc (NASDAQ:TENX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,497 shares of the specialty pharmaceutical company’s stock, valued at approximately $30,000. Susquehanna International Group LLP owned 0.35% of Tenax Therapeutics as of its most recent SEC filing.

Separately, Renaissance Technologies LLC increased its holdings in Tenax Therapeutics by 48.4% during the second quarter. Renaissance Technologies LLC now owns 359,441 shares of the specialty pharmaceutical company’s stock valued at $496,000 after buying an additional 117,200 shares during the period. 16.83% of the stock is currently owned by institutional investors and hedge funds.

Separately, ValuEngine raised shares of Tenax Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.



Shares of TENX opened at $1.19 on Wednesday. The company has a market cap of $8.05 million, a price-to-earnings ratio of -0.13 and a beta of 1.35. Tenax Therapeutics Inc has a twelve month low of $1.03 and a twelve month high of $6.39. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $1.26 and a two-hundred day moving average of $1.43.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Wednesday, August 14th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.17. On average, sell-side analysts expect that Tenax Therapeutics Inc will post -1.59 EPS for the current year.

Tenax Therapeutics Profile

Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.

Recommended Story: What is Elliott Wave theory?

Want to see what other hedge funds are holding TENX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenax Therapeutics Inc (NASDAQ:TENX).

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.